Migotanie przedsionków (AF) jest najczęstszym zaburzeniem rytmu serca stwierdzanym u osób z udarem mózgu. Uważa się je za główne źródło zatorowości kardiogennej stwarzające istotne ryzyko powikłań zatorowo-zakrzepowych. W pracy opisano dwa przypadki kliniczne osób z nowo rozpoznanym AF, u których jego pierwszą manifestacją był udar niedokrwienny mózgu.

Atrial fibrillation is associated with a few folds higher risk of stroke. Traditional vitamin K antagonists used in the prevention of stroke in patients with non-valvular atrial fibrillation are often not efficient enough due to their interactions with a broad range of substances including medicines or food ingridients and problems with monitoring the treatment. New oral anticoagulants pose an alternative for the vitamin K antagonists. They are equally efficient in the prevention of stroke, but are safer and have no requirement for routine coagulation monitoring. We present a case of a patient with atrial fibrillation, high risk of tromboembolism and recurring episodes of hemorrhages. Considering the possible complications, rivaroxaban was administered.

Introduction. Thromboembolic complications are the most severe consequences of atrial fibrillation (AF). AF is associated with significantly worse outcomes in patients with ischaemic stroke. The aim of the study was to evaluate the prevalence of AF, concomitant conditions, and in-hospital outcomes in patients hospitalized due to ischaemic stroke.

Arthritis in children as a result of a previous infection caused by Yersinia enterocolitica and Yersinia pseudotuberculosisInfections caused by Yersinia enterocolitica and Yersinia pseudotuberculosis, often referred to as Yersiriiosis, are classified as diseases occurring in human and animals which originate from their reservoir in a natural environment (sapronosis). Infection occurs orally by contaminated food or water, f pseudotuberculosis and Y enterocolitica are gram-negative, rod-shaped bacterias of the genus Yersinia, belonging to the family' of Enterobacteriaceae. They are enteric pathogens, responsible for triggering a large number of different symptoms ranging from diarrhea and abdominal pain, to more systemic ones such as fever or scarlatinform skinrash. Others may include myocarditis, Crohn's disease. Reiter's syndrome, chronic pancreatitis, ankylosing spondylitis, acute interstitial nephritis, Kawasaki syndrome, conjunctivitis, erythema nodosum, lymphadenopathy (1) and arthritis (2, 3).Reactive arthritis develops 1-4 weeks after gastrointestinal or urogenital infections caused by Yersinia. The finding of LPS structures of Yersinia in the synovial fluid of human joints is widely regarded to be of pafarnouht importance in the pathogenesis of arthritis (4-6).Studies suggest that a superantigen YPM, which is produced in vivo by Yersinia, is responsible for the induction of IgG synthesis in infected patients. Significantly higher antibody level in the patients with systemic symptoms and the presence of YPM-responsive cells in their lymph nodes suggest that this superantigen may have a key role in the disease process ( I ).Owing to the wide diversify of symptoms, Kers/nfo-associated arthritis can pose a complicated diagnostic problem and suggest a rheumatic origin of the disease. In that case, due to the impossibility of isolating the microorganisms at this stage of infection, the basis for the confirmation of diagnosis is the measurement of specific antibody levels against antigen О of Y. enterocolitica and T pseudotuberculosis (t, 8).The aim of the study was to determine the relationship between symptoms of arthritis and infections caused by Y. enterocolitica and Y. pseudotuberculosis in children. MATERIAL AND METHODSBlood samples of 68 randomly chosen patients from the Pulmunology and Reumatology Ward, Children Hospital of Lublin. Poland, were examined for the presence of antibodies against Yersiniae. A group of 17 children patients with the highest levels of immunoglobulins IgA. IgM and IgG against Yersinia was consequently chosen and carefully studied. A broad array of different clinical

Propafenone is used in the therapy of supraventricular arrhythmias. Its long-term use may be associated with the development of malignant ventricular arrhythmias. We present a case of a patient with paroxysmal atrial fibrillation, who was administered an oral dose of 600 mg of propafenone, which resulted in an episode of ventricular tachycardia. This article indicates that patients without severe heart failure subjected to therapeutic doses of propafenone are also exposed to the possibility of its adverse effects.